Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL).

Next Previous
Trial Profile

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL).

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosiglitazone (Primary) ; Fenofibrate
  • Indications Hypercholesterolaemia; Hypertriglyceridaemia
  • Focus Pharmacodynamics
  • Acronyms RAFAEL

Most Recent Events

  • 25 Feb 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
  • 07 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
  • 07 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top